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In recent studies, the reported prevalence of heterozygous familial hypercholesterolemia (FH) has been higher than in previous reports. 
Although cascade genetic screening is a good option for efficient identification of affected patients, diagnosis using only clinical criteria is 
more common in real clinical practice. Cardiovascular risk is much higher in FH patients due to longstanding low density lipoprotein cho-
lesterol (LDL-C) burden and is also influenced by other risk factors. Although guidelines emphasize aggressive LDL-C reduction, the 
majority of patients cannot reach the LDL-C goal by conventional pharmacotherapy. Novel therapeutics such as proprotein convertase 
subtilisin/kexin type 9 inhibitors have shown strong lipid lowering efficacy and are expected to improve treatment results in FH patients.
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INTRODUCTION
Familial hypercholesterolemia (FH) is a common autosomal 
dominant genetic disorder and is an important health issue [1,2]. 
Patients with FH are exposed to a lifetime burden of high low 
density lipoprotein cholesterol (LDL-C) and have significantly 
increased cardiovascular risk. Therefore, early and appropriate di-
agnosis in affected persons and prevention of vascular complica-
tions are critical. In this review, recent studies on the prevalence, 
diagnosis, vascular risk, and treatment of patient with FH are dis-
cussed. Particularly, the focus is on studies of heterozygous FH. 
PREVALENCE OF FAMILIAL 
HYPERCHOLESTEROLEMIA
The frequency of heterozygous FH has long been reported to be 
1/500 (0.2%), while that of homozygous FH has been reported 
to be 1/1,000,000 in many studies conducted in various coun-
tries around the world [3]. However, although heterozygous FH 
is influenced by diagnostic criteria including mutation positivi-
ty, the prevalence has been reported to be 1/217 in a very recent 
Danish study [4] and 1/250 in an American study using Dutch 
criteria [5].
CLINICAL AND GENETIC DIAGNOSIS
Clinical criteria most commonly used for diagnosis of FH in-
clude the Simon Broome Register Group criteria [6], Dutch 
Lipid Clinic Network criteria [6], and Make Early Diagnosis to 
Prevent Early Deaths (MEDPED) criteria [7]. A Japanese group 
has also developed their own criteria for FH [8]. Major items 
for these clinical diagnostic criteria are (1) severe hypercholes-
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terolemia; (2) physical findings such as xanthoma in the index 
case; and (3) family history of premature coronary artery dis-
ease (CAD) or severe hypercholesterolemia. While the above-
mentioned criteria designed in different countries show similar-
ity, they also show difference with respect to specific values 
(Table 1). For cost-effective and efficient diagnosis, many 
guidelines and expert groups recommend cascade genetic 
screening for family members. However, in real practice, diag-
nosis using only clinical findings from history taking, physical 
examination, and lipid profile is very common, especially when 
genetic screening is not available [1]. 
Most monogenic causes of FH are mutations of low density 
lipoprotein receptor (LDLR), apolipoprotein B (APOB), or pro-
protein convertase subtilisin/kexin type 9 (PCSK9) genes. All of 
these genes are involved in the pathway that clears circulating 
low-density lipoprotein [9]. Among monogenic FHs, about 90% 
are caused by mutations of LDLR, for which ≥1,200 different 
mutations have been identified [1]. However, even family mem-
bers who have the same mutation often have quite different 
LDL-C levels, responsiveness to lipid lowering therapy, and 
survival. Therefore, decision of whether to treat or the intensity 
of treatment depends mostly on the phenotype rather than geno-
type. In other words, the clinical importance of genetic diagno-
sis is limited, and clinical diagnosis is emphasized in real clini-
cal practice [10]. Pathogenic mutations are not identified in 
about 60% of clinically diagnosed FH patients, although the 
proportion differs according to the ethnicity or diagnostic crite-
ria. Most FH patients without a monogenic cause are suspected 
to have polygenic FH that is caused by a multiple lipid-related 
common variants [2]. 
Although LDL-C >500 mg/dL or a xanthoma in a child is 
suspicious for homozygous FH, some patients with homozy-
gous FH have lower LDL-C levels [11]. 
CARDIOVASCULAR RISK IN FAMILIAL 
HYPERCHOLESTEROLEMIA
The most critical complication in FH is life-time cardiovascular 
disease due to longstanding LDL-C burden (Fig. 1). It has been 
reported that 25% of affected women and 50% of affected men 
experience cardiovascular complications [12]. The risk of CAD 
is known to be 3.5- to 16-fold higher in heterozygous FH pa-
tients compared to non-FH individuals [13]. The results of stud-
ies on the risk of cerebrovascular disease have been inconsistent 
and the risk is not yet clear [14]. The guidelines recommend that 
risk assessment in patients with FH should not be made accord-
ing to European Systematic Coronary Risk Estimation or Amer-
ican Framingham Risk Score, because these scoring systems 
underestimate cardiovascular risk in FH [1]. Even with the same 
LDL-C levels, carriers of mutations for FH show higher risk for 
CAD [15]. In addition, cardiovascular risk in FH is also influ-
enced by other traditional risk factors, and these often also need 
to be considered when determining treatment [14,16]. 
THE GOALS AND RESULTS OF LIPID-
LOWERING TREATMENT AND NOVEL 
THERAPEUTICS
The main purpose of preventive measures in FH is the reduction 
of cardiovascular risk. Thus, it is essential to implement phar-
maco- and non-pharmacotherapy targeting hypercholesterol-
emia and other combined risk factors as well. As mentioned 
above, because vascular risk is very high and associated with 
cholesterol burden, lowering LDL-C is the mainstay of cardio-
vascular prevention in FH. Most recent guidelines indicate that 
it is desirable to reduce LDL-C to 50% of baseline levels or 
<100 mg/dL in adults with FH. Statins are the first-line agent 
Table 1. Characteristics of Four Clinical Diagnostic Criteria
Simon Broome Dutch MEDPED Japanese
Process of 
   diagnosis
Mutation or cholesterol plus  
xanthoma or family history
Sum of score for each item Cholesterol level alone Any two of cholesterol,  
xanthoma, or family history
Items Total cholesterol >290 or LDL-C 
>190 mg/dL; xanthoma; muta-
tion; family history of MI or  
hypercholesterolemia
Family history of CAD or hyper-
cholesterolemia; history of 
CAD, cerebral or peripheral 
vascular disease; xanthoma or 
corneal arcus; LDL-C ≥150–
330 mg/dL
Total cholesterol ≥290–360 or 
LDL-C ≥220–260 mg/dL
LDL-C ≥180 mg/dL; xanthoma; 
family history of hypercholes-
terolemia or CAD
MEDPED, Make Early Diagnosis to Prevent Early Deaths; LDL-C, low density lipoprotein cholesterol; MI, myocardial infarction; CAD, coronary ar-
tery disease.
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and ezetimibe or cholesterol-binding resins are recommended 
when needed [17]. Data from the United Kingdom have demon-
strated that the mortality of patients with FH decreased by 25% 
to 48% after introduction of statins [18]. Earlier treatment is im-
portant for efficient prevention of vascular complications. How-
ever, because the evidence is limited, there is no sufficient con-
sensus on when to start treatment in children with FH [19-21]. 
Lipoprotein apheresis can be considered in patients with per-
sistently high LDL-C after treatment, extremely high cardiovas-
cular risk, statin intolerance, or especially in patients who have 
homozygous FH [1]. Meanwhile, the achievement rate of LDL-
C goal (<100 mg/dL) is reported to be 11% [14] and a large 
part of patients do not reach the target. Therefore, PCSK9 inhib-
itors, recently approved lipid-lowering agents, are spotlighted 
and expected to meet the unmet medical need (Table 2) [22,23]. 
Although two PCSK9 inhibitors, evolocumab and alirocumab, 
have shown consistent and strong lipid-lowering efficacy, limi-
tation is their high cost [24]. Lomitapide inhibits microsomal 
triglyceride transfer protein and reduces very low density lipo-
protein (VLDL) assembly, whereas mipomersen blocks the 
translation of apoB and decreases VLDL synthesis. These two 
agents were approved for the treatment of homozygous FH. 
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Fig. 1. Low density lipoprotein cholesterol (LDL-C) burden in individuals with or without familial hypercholesterolemia (FH) as function 
of the onset of statin therapy. Adapted from Nordestgaard et al. [7], with permission from Oxford University Press. CHD, coronary heart 
disease; HDL-C, high density lipoprotein cholesterol.
Homozygous FH Heterozygous FH
Female sex
Smoking
Hypertension
Diabetes
↑Triglycerides
↓HDL-C
↑Lipoprotein(a)
Without FH
Threshold
for CHD12.5 Years 48 Years
53 Years
55 Years
Start high
dose statin
Start low
dose statin
35 Years
Table 2. New Therapeutics Approved for Familial Hypercholesterolemia
Lomitapide Mipomersen PCSK9 inhibitors (evolocumab, alirocumab)
Action 
   mechanism
Inhibition of microsomal TG transfer  
protein; reduction of VLDL synthesis
Antisense oligonucleotide that binds to 
mRNA and blocks apoB translation
Binds to plasma PCSK9, reduces endosomal 
degradation of LDLR
Efficacy Lowers LDL-C & apoB by 40%–50% 
on top of ongoing therapy
Lowers LDL-C & apoB by 20%–30% and 
lp(a) by 20%–25% on top of ongoing  
therapy
Lowers LDL-C by 50%–60%, apoB by 40%–
50%, and lp(a) by 20%–30%; 50% reduction 
of cardiovascular events in preliminary data
Safety GI disturbance (>90%), liver enzyme  
elevation (14%–34%), and hepatic  
steatosis
Injection-site reaction (>75%), influenza-
like symptoms (30%–65%), liver enzyme 
elevation (12%–15%), and hepatic steato-
sis
Largely well tolerated; slight injection-site  
reactions, neurocognitive and muscle-related 
symptoms
Remarks Approved in USA for hoFH Approved in USA, Canada, and Europe for 
hoFH
Approved in USA and Europe for FH
PCSK9, proprotein convertase subtilisin/kexin type 9; TG, triglyceride; VLDL, very low density lipoprotein; apoB, apolipoprotein B; LDLR, low densi-
ty lipoprotein receptor; LDL-C, low density lipoprotein cholesterol; lp(a), lipoprotein(a); GI, gastrointestinal; hoFH, homozygous familial hypercholes-
terolemia; FH, familial hypercholesterolemia.
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However, drug-related adverse events are relatively frequent 
and risk/benefit ratio needs to be taken into account for these 
drugs (Table 2) [22,23]. 
FAMILIAL HYPERCHOLESTEROLEMIA IN 
ASIA AND KOREA
Although Asian data on FH are not sufficient, its reported prev-
alence is similar to that of Western countries. The average cho-
lesterol level in Asian patients with FH is likely lower [25]. A 
recent Korean study suggested that the best cutoff values for 
predicting mutation-positive FH are total cholesterol 310 mg/dL 
and LDL-C 225 mg/dL [26]. In Asian patients, 80% to 100% of 
causing mutations were identified in LDLR, whereas the others 
were found in APOB or PCSK9 [25,26]. Three of 10 Korean FH 
patients revealed history of CAD. However, the achievement 
rate of LDL-C by conventional lipid-lowering therapy was not 
satisfactory [27]. 
CONCLUSIONS
FH is a relatively frequent genetic disorder. Diagnosis of FH by 
clinical rather than genetic criteria is more common in real 
world practice. Reduction of premature complications is most 
critical in patients with FH. Although, the majority of patients 
cannot reach a LDL-C goal by conventional pharmacotherapy, 
novel therapeutics such as PCSK9 inhibitors are expected to 
improve treatment results. 
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